It’s officially fall and that means cold and flu season is here. According to the CDC, Flu activity begins to increase in ...

The new results helped boost Moderna’s stock by more than 4% in early trading June 30, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.

Questions are answered by experts at the Oregon Health Authority, other state agencies or community partners. Questions and ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.